News

In this trial, which included an intensive diet and exercise behavior modification regimen, obese patients treated with Contrave, based on intent-to-treat and completer analyses, lost an average of

The Phase I proof of concept study compared intravenous CNS 7056 to placebo and a standard dose of midazolam, the current gold standard for procedural sedation. The anticipated

RGN-137 is a topical gel formulation of thymosin beta 4 peptide (Tâ4). The drug candidate was found to be safe and well-tolerated at all three dose levels, with

Under the terms of the proposal, each share of Exact Sciences would be exchanged for $1.50 in Sequenom common stock. This consideration would be subject to a floating

This program involves two clinical trials, taking place in the US (TG MV-006 trial) and Europe and North America (TG-MV-007 trial). The start of these pivotal clinical trials

UCB retains exclusive rights to re-purchase each of the five programs, following completion of initial clinical feasibility studies for each program, and assume the responsibility for further development

The company has also filed several patents associated with the development of peptides and proteins derived from ‘state-dependent’ physiologies to advance the treatment of a variety of human

The safety and efficacy of AllerNaze nasal spray in both seasonal allergic rhinitis and perennial allergic rhinitis have been well established in 14 controlled clinical trials involving almost

Delayed graft function (DGF) represents Quark’s second indication being evaluated for the systemically administered drug candidate in human clinical trials. This trial follows two currently enrolling Phase I